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Background: Treatment of major depression follows the guidelines from evidence-based 
medicine established algorithms; however, 50% of patients diagnosed with major depressive 
disorder do not respond to their first medication trial, and 70% may go through four treatment 
attempts before achieving remission.  
Purpose: To demonstrate the value of pharmacogenomic testing as a treatment-guidance 
technology in patients with resistant depression and assess healthcare providers' motivation to 
adopt the technology.  
Methods: A retrospective chart review of (N = 73) patients' treatment response measured by the 
pre-post PHQ-9 depression scale after pharmacogenomic guided medication intervention with 
descriptive statistics and paired t-test. The project also assessed providers' motivation to adopt 
and use pharmacogenomic testing by completing the providers' motivation scale (PMA) before 
and after viewing an educational session on the subject.  
Results: A significant improvement in mood with a mean decrease of 10 points in the post PHQ-
9 scores ( p = .000 < .001) in 53% of the subjects, and 33% had scores that ranked within 
remission. Most patients (60%) responded to 1.3 medications post pharmacogenomic treatment. 
The providers were motivated to learn new technology and gain knowledge derived from current 
information for patient care. 
Conclusions: These are significant findings corresponding to the new evidence research in 
pharmacogenomics supporting the use of the technology as a therapeutic resource for treatment-
resistant depression patients. 
          Keywords: pharmacogenomics, psychiatry, major depression, nursing, innovation    




A Quality Improvement Project to Assess the Value of  
Pharmacogenomic Testing in Adults Diagnosed With Major Depression 
Introduction 
           There is a treatment gap in adult patients diagnosed with a major depressive disorder who 
have failed two or more medications and remain symptomatic or are considered to have 
treatment-resistant depression (TRD). The practice guidelines for psychiatric evaluation and 
treatment from the American Psychiatric Association (APA) (2015) recognize that individuals 
may experience an inadequate response to medications or health and mood complications due to 
psychotropics' adverse events.  Authors like Giakoumatos and Osser (2017) and Stahl (2017) 
agreed that there are no treatment guidelines for patients' genotypes who failed antidepressants 
due to a lack of response or adverse events.  
          This quality improvement project compared Patient Health Questionnaire - 9 (PHQ-9) 
scale score changes before and after medication’s guided intervention from pharmacogenomic 
testing (PGx) in adult patients who failed more than two antidepressants. The goal was to 
identify the value of pharmacogenomic testing as a personalized treatment resource in patients 
with genomically idiosyncratic needs vs. the non-response to treatment as usual (TAU). A 
second goal included the assessment of healthcare providers’ motivation to adopt this 
technology. 
Background 
          Major depressive disorder (MDD) has the highest prevalence in mental health conditions, 
with a 7.1 % among the adult population in the United States (USA) (National Institute of 
Mental Health, [NIMH], 2019). The results from the Sequenced Treatment Alternatives to 




respond to their first medication trial, and 70% of patients may go through four treatment 
attempts before achieving remission (NIMH, 2006). Similar findings from Warden et al. (2007) 
identified that less than 50% of MDD patients would achieve remission after two antidepressant 
trials.  
          The STAR*D psychopharmacology algorithm presented four levels of antidepressant 
management with subsequent treatment recommendations after each level's failure (Gaynes et al. 
2008) (Appendix A). The first level starts with the use of citalopram. If the patient failed to 
respond or could not tolerate it, will switch to level two with venlafaxine extended-release or 
sertraline, or augmentation with bupropion sustained-release and cognitive therapy. For non-
respondent individuals, level three proposed trials of mirtazapine or nortriptyline and 
augmentation with lithium or T3 thyroid hormone. Finally, level four recommends combining 
mirtazapine and venlafaxine extended-release or monoamine oxidase inhibitors (MAOIs) like 
tranylcypromine (Parnate). 
          Correspondingly, the psychopharmacology algorithm project at the Harvard South Shore 
Program (Appendix B) by Giakoumatos and Osser (2017) incorporates the first-line use of 
sertraline, escitalopram, or bupropion for the treatment of outpatient unipolar depression. If the 
patient does not respond, switch to a dual-action agent like venlafaxine or mirtazapine. The 
algorithm includes serotonin selective reuptake inhibitors (SSRIs) alone or combined with 
lithium or Wellbutrin for augmentation, also transcranial magnetic stimulation (TMS), 
supplements like omega-3s, and atypical antipsychotics. Patients who fail two antidepressants 
will be considered to have treatment-resistant depression (TRD). The group guidelines suggest 




preferences before a third medication trial (APA, 2015; Giakoumatos & Osser, 2017; Stahl, 
2017).           
          Polypharmacy is a practice that has increased in psychiatry over the last 20 years 
(Shrivastava, 2019). Treatment-resistant depression (TRD) patients are frequently under 
psychiatric polypharmacy with two or more prescriptions unless discontinuing a medication due 
to adverse effects. The use of more than one medication increases drug interactions, potential 
adverse effects, morbidity, and mortality (Sarkar, 2017). Johnston et al. (2019) and Mrazek et al. 
(2014) found in a systematic literature review that TRD patients who have failed more than two 
medication courses will experience a reduced health-related quality of life (HRQoL). According 
to the authors, these patients will also have higher relapse rates, increased mortality, and 
additional medical direct and indirect costs to society of $29 to 48 billion dollars a year.   
          The science of pharmacogenomics has been evolving since the 1960s, intending to find 
genetically congruent medications based on the individual’s genetic markers or metabolic profile 
(Charlab & Zhang, 2013). Different medical specialties, including psychiatry, benefit from 
pharmacogenomics to identify patients’ metabolic biomarkers with strengths or weaknesses in 
the Cytochrome P-450 (CPY450) family (pharmacokinetics), and variations in genetic 
morphology receptors (genotype) that may affect drug response and result in SSRI resistance 
(Vadodaria et al., 2019).  
          Currently, the Food and Drugs Administration (FDA) recognized four genes evidence-
based verified pertinent to psychopharmacology, cytochrome P450 2D6 (CYP2D6), cytochrome 
P450 2C19 (CYP2C19), human leukocyte antigen, B type, allele 15:02 (HLA-B*15:02), and 
human leukocyte antigen, A-type, allele 31:01 (HLA-A*31:01), (Hicks et al., 2016; Miller, 




elicited by companies that advertise the test will predict medications for an individual. Recent 
and ongoing clinical trials show that pharmacogenomic testing (PGx) offers patients congruent 
medication alternatives compatible with their genotype needs.    
Review of the Literature 
          This review of the literature explored pharmacogenomic testing as an alternative to guide 
the treatment of patients who have failed two or more antidepressants. Search engines from 2014 
to 2020 included the Cumulative Index of Nursing and Allied Health Literature (CINAHL), 
PubMed Central of the National Library of Medicine, and Google Scholar for the medical 
subject headings (MeSH): pharmacogenomics, psychiatry or psychiatric or mental health, 
nursing, clinical guidelines, randomized controlled trials, and systematic reviews.    
          Inclusion criteria followed the levels of evidence I to II recommended by the National 
Guideline Clearinghouse (U.S. Department of Health and Human Services, n.d.), focusing on 
randomized controlled trials (RCT), clinical guidelines, controlled studies, prospective and 
retrospective studies, and systematic reviews. The exclusion criteria was comprised of level IV 
editorials, letters, opinion articles, six duplicated articles, and two ongoing pharmacogenomic 
clinical trials in Europe and Oregon, United States.   
          Most articles were available through the University of Massachusetts EBSCO host 
database.  The search revealed 47 articles in the time frame for pharmacogenomics and 
psychiatry or psychiatric or mental health and randomized controlled trials.  The final selection 
included 15 articles: the guidelines from the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and the Dutch Pharmacogenetics Working Group, five Level I RCTs 
comparing treatment as usual vs. pharmacogenomic testing, one review of three randomized 




reviews. There were no results under pharmacogenomics and psychiatric nursing, and 
randomized clinical trials. However, for the terms “nursing and clinical trials,” six nursing 
articles included two Level IIB quasi-experimental retrospective studies, both covered in this 
review.  
Clinical Guidelines    
          The U.S. Clinical Pharmacogenetics Implementation Consortium (CPIC)  and the Dutch 
Pharmacogenetics Working Group in the Netherlands share therapeutic recommendations for the 
dosing of antidepressants, including tricyclics (TCAs) and Selective Serotonin Reuptake 
Inhibitors (SSRIs) (Bank et al., 2018; Fabbri, & Serretti, 2019).  All clinicians who prescribe will 
benefit from the guidelines recommendations appropriate for patients with genotype variances 
(Hicks et al., 2015, 2016).  
          The guidelines identified two essential pharmacokinetic genes involving the metabolism of 
most antidepressants (TCAs and SSRIs) based on levels of evidence I and II, cytochrome P450 
2D6 (CYP2D6) and cytochrome P450 2C19 (CYP2C19) (Bank et al., 2018; Hicks et al., 2015, 
2016). The classifications of genotypes are normal, intermediate, ultra-rapid, and poor 
metabolizer. Both consortiums agree on the need for dose adjustment when prescribing 
antidepressants to patients identified as ultra-rapid and poor metabolizers or consider an 
alternative medication (Bank et al., 2018; Hicks et al., 2015, 2016). Lack of knowledge of the 
patient's possible genotype variants will result in the prescriber's treatment as usual (TAU) 
choices, perpetuating the potential failure, adverse events, or inappropriate polypharmacy.   
Evidence-Based Psychopharmacology 
          Greden et al. (2019), in a rater patient-blind randomized controlled trial (RCT) of 




with N = 1167 MDD patients, found the guided group had significant results for response and 
remission rates p = 0.013 and p = 0.007 respectively. However, results were not significant for 
symptom improvement, possibly since some TAU group patients were already taking genetically 
congruent medications. In a post hoc analysis of the GUIDED data, Dunlop et al. (2019) found 
significant improvement, response, and remission rates at eight weeks using the Hamilton 
Depression scale 6 (HAM-D6) in patients in the GUIDED group and the TAU group with the 
prescription of personalized medications.  
           In a Level I RCT for outpatient and inpatient Spanish public hospitals, Pérez et al. (2017) 
found that MDD patients in the pharmacogenomic guided group had a higher response and better 
tolerability to antidepressants than TAU groups, but not sustained response. In China, Xiao-Xiao 
et al. (2019) had comparable results in a Level II case-control trial. Individuals identified by 
testing with the  ABCB1 TT genotype of rs2032583 improved treatment response to selective 
norepinephrine reuptake inhibitors (SNRIs).   
          Contrary to the previous results, Ruaño et al. (2020) randomized patients’ treatment at the 
Institute of Living at Hartford Hospital based on their CYP2D6 genotype vs. TAU to compare 
the length of stay (LOS) and readmissions rate (RAR) between groups. They found no statistical 
differences between groups; however, the authors identified genetic polymorphisms in the study 
population and recognized the barrier of physicians’ non-compliance with pharmacogenomic test 
recommendations. Solomon et al. (2019) had similar inconsistent findings for treatment response 
or improved clinical outcomes in PGx testing of CYP2D6 and CYP2C19.  
          A pragmatic randomized controlled trial by van der Schans et al. (2019) tested CYP2D6  
in depressed elderly patients to determine the benefits of accelerating nortriptyline or venlafaxine 




The researchers found no significant mean time differences between groups to reach adequate 
doses. However, more patients (n = 24) in the genotyped group who were poor and intermediate 
metabolizers (PM, IM) reached medication levels vs. the control group (n = 16). The researchers 
also found lower adverse events in the external control group (normal metabolizers) than the 
genotype groups. The findings reflect the benefits of PGx for appropriate dosing in individuals 
with PM or IM genotypes in accordance with the clinical guidelines.  
          In a review of three Level I RTCs, Altar et al. (2015) evaluated pharmacogenomic guided 
medication versus treatment as usual (TAU) based on Hamilton – Depression 17 (HAM-D17) 
and Beck Depression Inventory (BDI), respectively. Findings showed that patients with 
pharmacogenomic guided treatment had a 2.3 higher odds ratio of clinical response than patients 
in TAU. Congruent with these, Tanner et al. (2018) found in a Level II open-label prospective 
study that patients with moderate to severe depression had a 31% greater improvement in 
response and 15.2 % greater remission rates when using pharmacogenomic testing. 
          There are two Level II pharmacogenomic testing studies in recent nursing literature. One is 
a quality improvement pre – post test design by Conley et al. (2020) using pharmacogenomic 
testing in the psychotropic management of patients with chronic mental illness. The researchers 
found that patients with psychotropics guided by PGx decreased symptoms, increased treatment 
engagement, and improved community function. In a retrospective six-month pre-post chart 
review of patients guided medications adjustments post pharmacogenomic testing, White et al. 
(2018) identified patients improved tolerability and decreased side effects.  
   In systematic reviews of pharmacogenomic testing for patients’ outcomes, benefits, and 
testing cost-effectiveness, Peterson et al. (2017) and Rosenblat et al. (2017) found mixed 




agreed that there were few pharmacogenomic randomized controlled trials before 2018, therefore 
limited evidence. On the other hand, a retrospective cohort study from Sussman et al. (2019) 
established the cost benefits of using pharmacogenomic testing with potential health care savings 
of over $3,000.00 dollars a year in individuals with treatment resistant depression.  
 The validity and utility of pharmacogenomic testing in recent research illustrates the  
improved response and remission rates for depression in patients with genotype deviations. It 
also showed the opportunity to anticipate medication dosing, drug-gene interactions, response 
deficits, or side effects (Benitez et al., 2015). The Food and Drug Administration (FDA) 
recognizes pharmacogenomics’ use to identify individuals who will or will not respond to 
medications, avoid adverse events, and improve drug response (FDA, 2020). Their guidelines 
include drug labeling with data enforcing risks in drug exposure and adverse events, genotype 
dosing recommendations, drug mechanisms, and drug target and disposition genes (FDA, 2019). 
The agency also bounds pharmacogenomic testing companies from making false claims or 
advertisements for predicting patient–medications response (FDA, 2019). 
Theoretical Framework 
          The Diffusion of Innovation Theory by Everett Rogers (2003), provided the ground for 
this DPN project (Appendix C). The communication model promotes the adoption of new 
behaviors or ideas by the target groups, in this case, health professionals, organization leaders, 
and patients. Rogers (2003) recognizes that the acquisition of ideas in a population takes time for 





          According to Rogers (2003) the five categories of innovation adopters are: innovators, 
early adopters, early majority, late majority, and laggards. All will go through the stages of 
awareness, the decision to adopt or reject, initial use, and continued use of the innovation at their 
own pace. The individual’s choice to adopt the new idea will be based on five factors: 1) the 
belief that the new idea is better than the old; 2) the idea must be consistent with the adopters' 
values and needs; 3) level of difficulty to understand or use; 4) testing capability; 5) observable 
results – outcomes (Rogers, 2003).            
         The diffusion process requires knowledge to engage, persuade, and maintain change 
(Rogers, 2003). In a systematic review of oncology physicians' genomic literacy, Ha et al. (2018) 
examined Rogers’ three types of knowledge in the translation and adoption process: awareness, 
how-to, and knowledge principles. Their findings reflected that 87% of these physicians had an 
awareness of the different cancer genetic assays, but only 20 to 40% were ordering the assays. 
This data confirms that awareness is not tantamount to applying new technology.  
          The slow adoption of pharmacogenomic testing by healthcare providers is an ongoing 
debate that resonates with the Diffusion of Innovation Theory. Some scientific groups are in 
support, while others prefer to continue with the traditional treatment as usual or TAU until more 
evidence is available. In a meta-data analysis of 36 studies, Veilleux et al. (2020) found that 
physicians were not ordering pharmacogenomic testing due to recognizing their knowledge 
deficits in the topic. This project included an education component to promote providers with an 
evidence-based understanding of pharmacogenomics and the conviction that PGx testing 







          This quality improvement program did a record review in a community mental health 
agency in Western Massachusetts of their current use of pharmacogenomic testing to identify 
patients’ response and remission to genetically sound medications measured by the Patient 
Health Questionnaire 9 (PHQ-9). The project also surveyed providers’ motivation to adopt 
pharmacogenomics before and after an educational presentation to motivate and strengthen their 
adoption and knowledge in using the technology.  
The timeline (Appendix D) started in October 2020 with a two-year retrospective chart 
review from November 2018 to October 2020 of patients diagnosed with major depression 
(MDD) who received pharmacogenomic testing. Next, providers including physicians, nurses, 
administrators, and a group of therapists received a Survey Monkey consent via email to 
participate in the project (Appendix E), and if acceded, continued to the Provider Motivation 
Adoption (PMA) Pre-scale (Appendix F). The scale measures motivation to adopt and maintain 
the use of innovative technology (Hatz et al., 2017). During November 2020, the providers 
received a 15 minutes video powerpoint education in pharmacogenomics and related literature 
(Appendix G). A post-survey (Appendix H) was available to the providers and staff during 
February 2021.  
For the chart review, the inclusion criteria were adults over 18 years old diagnosed with 
MDD, a history of two or more medication failures, and previous pharmacogenomic testing at 
the agency. Exclusion criteria were patients with other diagnoses (e.g., bipolar disorder), 
concurrent transcranial magnetic stimulation treatment (TMS), or drop out from treatment before 
guided intervention.        




part of the electronic medical record (EMR), and providers could fill the PMA scales online.  
The education program was a 15 minutes video PowerPoint delivered by email to watch in their 
own time. Using the electronic platforms provided access and saved the cost of materials.  
Goals, Objectives, and Expected Outcomes  
          The project’s main goal was to assess the value of pharmacogenomic testing in the 
psychotropic management of adults diagnosed with major depressive disorder (MDD) who have 
failed two or more medications. A secondary goal was to promote the adoption and use of 
pharmacogenomic testing by medical providers. To achieve this, the student followed these 
objectives (Table A1):  
1.  Evaluated the response to pharmacogenomic guided medications in patients tested from 
     2018 to 2020 with the Patient Health Questionnaire - 9 scales by February 2021.  
2.  Assessed providers' motivation to adopt pharmacogenomic testing with the provider   
     motivation adoption scale (PMA scale) (Hatz et al., 2017) during November 2020.  
3.  Promoted providers' adoption of pharmacogenomic testing with education on the 
     topic by November 2020.  
          The expected outcomes were greater efficacy in treating depression in the project subjects 
as evidenced by improved treatment response with a minimum drop in five points from baseline 
in the Patient Health Questionnaire - 9 scale, or remission with four or less total points on the 
scale. The secondary outcome expected and increased in provider motivation to use 
pharmacogenomic technology measured by an increase in the PMA scale results after the 




Project Site and Population  
          A community mental health agency in Western Massachusetts was the site for this project. 
The agency serves a diverse population of over 12,000 individuals and families from different 
socio-economical, racial, and cultural backgrounds. The agency is composed of multidisciplinary 
mental health professionals who offer a variety of behavioral and psychopharmacology 
modalities. In 2018 the medical director incorporated pharmacogenomic testing for medication 
guidance in patients non-responsive to treatment, and in 2019 added the Transcranial Magnetic 
Stimulation (TMS) program.  
          The medical team comprises psychiatrists, child psychiatrists, primary care physicians, 
advanced practice nurses, and registered nurses. Providers follow treatment as usual (TAU) 
medication protocols based on major depression (MDD) guidelines.  Pharmacogenetic testing is 
available in the agency and covered by MassHealth, Medicaid, Medicare, and some commercial 
insurances. However, due to providers’ time limitations with a high volume of patients and 
possible knowledge gaps in using the pharmacogenomic report, the testing is not used as a 
standard practice in treatment resistant patients who failed the recommended algorithms. 
Description of the Group         
          The retrospective review's target population was 123 records of adults diagnosed with 
MDD who failed at least two antidepressants and had pharmacogenomic testing from November 
2018 to October 2020. The providers' educational intervention included four physicians, five 
nurses, three administrators, and a group of 15 randomly selected psychotherapists. The group 
received via email a Survey Monkey consent to participate in the project (Appendix E), and if 
acceded, continued to the Provider Motivation Adoption (PMA) Pre-scale (Appendix F) and 




Measurement Instruments  
          For the record review, patients had filled the self-assessment Patient Health Questionnaire 
- 9 (PHQ-9) (Appendix I) ideally on their first interview and during treatment. The PHQ-9 is an 
ordinal scale that assesses degrees of depression. Scores ranging between 5 - 9 are mild 
symptoms, and scores ranging from 10 – 27 are considered depression from moderate to severe. 
Levis et al. (2019) found a combined sensitivity of 0.88 and specificity of 0.85 for a cut-off score 
of 10 or above.  
          The educational session and assessment of motivation, providers were engaged in the 
project during the monthly zoom team conference and received by email a pre and post-test 
based on the Physician Motivation Adoption (PMA) scale from Hatz et al. (2017) (Appendix F, 
Appendix H). The PMA scale is a five-point Likert scale that measures physicians’ motivation to 
adopt different medical technology or devices (Hatz et al., p. 533). It has excellent reliability and 
validity with an acceptable Kaiser-Meyer-Olkin (KMO) test value of 0.76. For this project, and 
after obtaining authorization from the author (Appendix J), the scale was renamed the Provider 
Motivation Adoption scale to allow non-physician providers to participate in this project 
(Advanced Practice Nurse, Nurses, clinicians, and administrators). The PMA scale was labeled 
as Pre-PMA (Appendix F) for the initial assessment and Post-PMA (Appendix H) after the 
educational intervention with additional comments option in both. 
Providers Education Program 
          Due to Covid quarantine and providers’ availability limitations, the DNP student submitted 
by email a video education program in pharmacogenomics (Appendix G) for the agency 
providers, including psychiatrists, nurses, and therapists, after the online pre-test assessment. The 




strategies to understand the pharmacogenomic report's clinical application. The presentation 
combined various sources, including authorized material from the Neuroscience Education 
Institute in California, USA (Appendix K). After one to two months from the video education, 
the providers received the post-PMA via SurveyMonkey email link. 
Data Collection and Analysis  
          The data was collected from patients' pharmacogenomic reports at the Myriad AssureRx 
secure website, the PHQ-9 scores, and their demographic data from the electronic health records. 
Thirty subjects were missing PHQ-9 scales and called to update their information. The input was 
organized in an excel sheet and transferred to the Statistical Package for Social Sciences (SPSS) 
program (Appendix L ).  The statistics included patients' demographics (age, gender, race-
ethnicity), changes in mood response or remission based on PHQ-9 scales pre-post 
pharmacogenomic guided treatment, number of medications before and after the PGx guided 
report, comorbid personality disorders (borderline personality disorder and history of substance 
use), and genotype report data (e.g., CPY450 variations).  
          The analysis included descriptive statistics of the group demographics, an average of 
medications before and after pharmacogenomic testing, comorbid borderline personality disorder 
vs. history of substance use responses, and genotype findings. Paired t-test was used to examine 
the difference between PHQ-9 scores before and after pharmacogenomic guided medication. Due 
to sample size limitations and cross-over comorbid diagnoses within the sample subjects, 
inferential statistics were not appropriate. Nonetheless, crosstabulation allowed to examine the 
relation of post-PHQ-9 scores and subjects with comorbid borderline personality disorder and 




          The providers' motivation data were obtained from their responses to the PMA pre-post 
scales via SurveyMonkey on their website under the student's secure account. Descriptive 
statistics described their responses and motivation to adopt the new technology after the 
education intervention.  
Ethical Considerations and Protection of Human Subjects 
          To comply with the University of Massachusetts, Amherst (UMass) Internal Review Board 
(IRB), the student obtained the agency approval for the Quality Improvement Project for the 
retrospective chart review (Appendix M). The agency providers received a consent form for their 
participation in the PMA survey in early November 2020. The pharmacogenomic reports from 
Myriad AssureRx are the product the agency uses. The student discloses no bias or conflict of 
interest in the pharmacogenomic report or the company. 
          The Health Insurance Portability and Accountability Act ([HIPPA], 2003) requirements 
for retrospective studies emphasize the use of patient non-identified data. Therefore, patients’ 
data were assigned a number in the pharmacogenetic reports, PHQ-9 scales, patients’ diagnoses, 
and demographics. The student destroyed any list of cases after the data was collected. All 
electronic files containing identifiable information are password protected to prevent 
unauthorized users' access, and only the project coordinators have access to the passwords. 
          The nursing Code of Ethics standards reiterate the nurse's responsibility to guarantee the 
patient's interests, safety and protect their rights (Winland-Brown et al., 2015). The student 
guaranteed the patient's and staff's best interests, protected their confidentiality and safety during 






  The record review was completed between October 2020 to February 2021. It included 
123 records of adults over 18 years old diagnosed with major depressive disorder (MDD) who 
failed more than two antidepressants and had pharmacogenomic testing (PGx) for treatment 
guidance. The final sample consisted of 73 cases that met the inclusion criteria. Patients with a 
diagnosis of bipolar disorder (16), in concurrent transcranial magnetic stimulation TMS (10), and 
closed before followed PGx treatment (24) were excluded. The providers' survey, including 
video education, was emailed to 27 physicians, nurses, clinicians, and administrators, out of 
which 12 responded to the Pre-PMA survey, and only three responded to the Post-PMA survey 
despite reminders by email.   
Record Review Demographic Characteristics 
          The 73 patients diagnosed with major depression ages ranged from 18 to 71, with a mean 
age of 44 years old. A majority (72.6% ) were females and 27.4% males, predominantly White 
European-American 86.3%, with White Hispanic 8.2%, and 5.5% Black African-American.   
          Before pharmacogenomic testing, 17 patients (23.3%) had an average of four medications, 
16 (21.9%) had eight to eleven medications, and 15 (20.5%) had five to seven medications. The 
average number of medications after pharmacogenomic guided medication was 1.36 in 44 
patients (60.3%), and 18 (24.7%) had two to four medications before responding to treatment.  
Pre-Post PHQ-9 Scores Findings 
          To examine the benefits of pharmacogenomics testing, Table 2 presents the pre-post PHQ-
9 depression scores after the pharmacogenomic guided medication intervention. The PHQ-9 




9 mild depression, 10-14 moderate depression, 15-19 moderate to severe depression, 20-27 
severe depression.  
Table 2 
PHQ-9 Pre – Post and Difference Scores  
 
                        Pre 
                 PHQ-9 score 
            Post 







                                    
                                   65                          
                     




  18.95 
                       
                       9.08 
 





                       
                       6.25 
   





                          
                          7 
                     
                       12 
  




                                     5 
 
                       13 
 
          The post-PHQ-9 produced a mean of 9.08 points with 6.25 standard deviations (SD) vs. a 
pre-PHQ-9 mean of 18.95 with 4.18 SD. This represents a mean difference or decrease of 10 
points in the post-measurement or treatment response with more than five points decrease. 
Interestingly, the post scale (n = 65) has a mode or most frequent score of five points (minimal 
depression) in 13.7% of the group vs. a previous mode of 22 (severe depression) in 12.3% of the 
subjects in the pre-PHQ-9. It must be noted there were nine missing values in the pre-data and 
eight missing in the post-scores. The discrepancy resulted from the PHQ-9 scale not being part of 
the agency's routine measurements for all patients; therefore, not all subjects had the scale before 
or after the PGx testing. For this reason, the analysis follows the reported data from SPSS. 




distribution with a Pearson's coefficient of skewness Sk2 = -.39 (-0.5 to 0.5 approximately 
symmetric).  
          To further assess the difference between the pre-post PHQ-9 scales, a paired t-test was 
used with results presented in Table 3. 
Table 3 
Paired Samples Test 
        





    










10 5.605 .706 8.588 11.412 14.412 62 .000 
 
Note. Correlation r =.488 
        
The paired t-test for the pre-post PHQ-9 scores revealed a moderate association with a 
correlation of r=.488, indicating a positive change between the scales where scores decreased 
linearly after the pharmacogenomic intervention. The data reflects a statistical mean difference 
with significant p=.000 < .001, which reveals patients’ response to treatment with a significant 
decrease of 10 points mean in the post PHQ-9 scores or treatment response (5 – 9 mild 
depression) after the pharmacogenomic guided medication changes. The results do not suggest 
remission due to most of the scores in the "5-9 mild depression and 10-14 moderate depression " 




This project did not include patients with multiple comorbid diagnoses (e.g., anxiety, 
post-traumatic stress), except subgroups with a diagnosis of borderline personality disorder 
(BPD) and substance use, as illustrated below in Table 4. 
Table 4 
 






















No Comorbid Diagnosis  










































Note. N = 73 
 
aSome of the percentages exceed 100% due to overlap. 
          A subgroup with the diagnosis of comorbid borderline personality disorder (BPD) was 
identified in 26% of individuals. Twenty percent were females with predominant ages of 29 to 39 
and 51 to 50 (n=6 in each age subgroup). In terms of comorbid borderline personality disorder 
and substance use history, the results identified eight (10%) of females with comorbid 
personality diagnosis and substance use history. There were four (5%) males diagnosed with 
BPD and four (5%) with combined BPD and substance use history. The more significant number 
of females in the sample and the fact that they have diagnosed BPD 3:1 ratio to males are 




          There was a past substance use history in 39 (53%) of the 73 patients, which included 
alcohol and cannabis and/or cocaine and/or opiates (19.2%,) cannabis (8.2%,), opiates (6.8%), 
cocaine (1.4%), opiates and cannabis (1.3%), and active cannabis use (11.8%). In the gender 
subgroups, 19% of the males, half of the subgroup, had past substance use vs. 34% of the 
females. The “National Survey on Drug Use and Health” by McCance-Katz (2019) identified 
19.3 million Americans over 18 years old with a substance use disorder (SUD), 20.6 million with 
a mental illness, and an overlap of 9.5 million individuals with both SUD and mental illness. The 
sample data had a higher proportion; more than half of the patients had a SUD history, probably 
due to the sample size limitation.   
          To explore any relation in the post PHQ-9 scales of patients with comorbid BPD or 
substance use history vs. no comorbidities, Table 5 shows a crosstabulation.  
Table 5 
Post PHQ-9 in Patients With no Comorbidities vs. BPD and Hx. SUD  
 





  N               % 
 
    Borderline 
    Personality 
    Disordera 





       N               % 
 
0 – 4   14 21%    1  1.5% 7 10% 
5 - 9   15 23%    9 13% 12 18% 
10 – 14   10 15%    2  3% 6 9% 
15 - 19    4  6%    3  4% 2 3% 
20 - 27    2              3%    4             6%       6                9% 
 
Note. N=65. Missing values.  




          All three subgroups had most subjects post PHQ-9 scores in the “5 – 9 mild depression” 
range with a highest 23% in the “no comorbid diagnosis,” 18% “history of substance use,” and 
the lowest 12% in “borderline personality disorder.”  We can observe 21% and 10% of “0 – 4 
none to minimal depression” or remission in the “no comorbid diagnosis” and “history of 
substance use” subgroups. The patients in the history of substance use had more scores 10% > 
1.5%  in the “0 – 4 none to minimal depression” and 18% > 12%  in the “5 – 9 mild depression” 
than the BPD subgroup. The findings indicate that individuals in the borderline personality 
disorder subgroup had lower responses post pharmacogenomic intervention.  
          Other interesting findings included the subjects' genotypes for the serotonin transport gene 
SLC6A4 with a 45.2% L/S variant "Intermediate Sensitivity" and a 27.4% S/S variant with 
"Increased Sensitivity." These variants will result in decreased serotonin transport and reduced 
response to SSRIs antidepressants. The serotonin receptor genes HTR2A A/A had a 15.1% and 
the HTR2A G/G a 39.7% of the subjects. In both cases, evidence research demonstrated 15% and 
42% of potential side effects to SSRIs, respectively. Table 6 below presents the sample findings 
























































  0.0% 
 
  5.5% 
 
  2.7% 
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  0.0% 
 







  1.4% 
  
  8.2% 
 
  0.0% 
 
  8.2% 
 




  0.0% 
 
 
Note. N = 73 
          The most common genotypes in the sample (50.7%) were with the ultrarapid (fast 
metabolizer) enzyme CYP1A2. This finding is not relevant for our discussion since the enzyme 
is not responsible for metabolizing antidepressants. However, it is the main pathway for 
medications like Clozaril, Zyprexa, and others (Flockhart, 2008) to treat psychosis and 
schizoaffective disorders.  
The following frequent group was in the  “intermediate metabolizer” (IM) category with 
37% for the CYP2B6 enzyme responsible for the antidepressant bupropion (Wellbutrin), and the 
CYP2C9 enzyme 35.6%, which participates in the metabolism of amitriptyline (Elavil), doxepin 
(Sinequan), fluoxetine (Prozac), venlafaxine (Effexor), and valproic acid (Depakote) (Flockhart, 
2008). The enzyme CYP2C19, which metabolizes citalopram and escitalopram (Celexa and 
Lexapro) and several TCAs, had a 20.5% IM, and UGT2B15, which metabolizes sedatives often 




          Finally, 19.2% of the patients were "Intermediate Metabolizer" and another 11% "Poor 
Metabolizer for the enzyme CYP2D6, which metabolizes 25% of all prescription drugs and 
many antidepressants like Prozac, Paxil, Cymbalta, Effexor, and TCAs.  The awareness of these 
genotype deficiencies in a population will help prescribers dose antidepressants according to 
clinical guidelines to prevent adverse reactions in individuals who are intermediate or poor 
metabolizers or avoid drugs metabolized by those enzymes.  
Participants Motivation to Adopt  
           Another piece of this evaluation was getting the participants (physicians, nurses, 
administrators, and clinicians) to complete the Provider Motivation Adoption Scale (PMA scale) 
regarding their motivation to use new technology in their work. The motivation to the adopt scale 
was sent to a group of clinicians and administrators during November 2020. Of the 27 healthcare 
professionals, only 12 responded to the Pre-PMA survey, with only eight surveys complete 
enough to use the data.  
          Of the 12 that responded: 12.5% were physicians, 25% nurses, 25% administrators, and 
37.5% clinical therapists. Their ages range from 55 to 64 with 62.5%, 35 to 44 with 25%, and 45 
to 54 with 12.5%. Sixty-two percent (5) of the respondents were females, 25% male, and 12.5% 
"other" gender. Although only one prescriber was in this group, many were nurses who could 
influence care decisions. Two were administrators who could influence policy and financial 
expenditures in the organization. Despite having a small number of respondents, some interesting 








Providers Pre-Motivation Adoption Scale  
                                                            Strongly         Disagree          Neutral         Agree          
Strongly          
Items                                                Disagree (1)             (2)                   (3)              (4)              
Agree (5)      
Functional      
F1 Reliability                          0.0%           
12.5% 
     
12.5% 
   50.0%  25.0%  
F2 Time Saving                      0.0%           
12.5% 
       
0.0% 
   62.5%  25.0%  
F3 Practical                             0.0%           
12.5% 
     
12.5% 
   62.5%  12.0%  
F4 Facilitation                         0.0%            
0.0% 
     
37.5% 
   62.5%  0.0%  
Conformity      
Con1 Expectations                     12.5%          
37.5% 
   50.0%    0.0% 
 
 0.0%  
Con2 Advice                              12.5%          
37.5% 
   50.0%    0.0%  0.0%  
Con3 Utilization                          0.0%          
37.5% 
   50.0%   12.5%  0.0%  
Con4   Competition                     25.0%          
37.5% 
   25.0%   12.5%  0.0%  
Con5 Majority opinion              12.5%          
25.0% 
   12.5%   50.0%  0.0%  
Power      
P1 Recognition                      12.5%          
50.0% 
 25.0%  12.5%  0.0%  
P2 Career advance                 25.0%          
25.0% 
 50.0%    0.0%  0.0%  
P3 Opinion leader                  12.5%          
37.5% 
 37.5%   12.5%  0.0%  
P4 Decision makers               12.5%            
0.0% 
  50.0% 25.0%  12.5%  
P5 Future earnings                 12.5%          
37.5% 
  50.0%  0.0%   0.0%  
P6 Pioneer                               0.0%             
0.0% 
  37.5% 50.0%  12.5%  
Hedonic      
H1 Passion                               0.0%           
25.0% 
50.0% 25.0%   0.0%  
H2 Satisfaction                         0.0%           
0.0% 
25.0% 75.0%   0.0%  
H3 
 
Excitement                          0.0%           
0.0% 
0.0% 75.0%  25.0%  
H4 Joy                                      0.0%            
0.0% 
12.5% 87.5%   0.0%  
H5 
 
Enthusiasm/personal reward  0%           
0.0% 
50.0% 50.0%   0.0%  
Patient Benefit      
PB1 
 
Despite High Cost              0.0%           
0.0% 
25.0% 37.5%  37.5%  
PB2 
 
Increased effort                  0.0%           
0.0% 
 0.0% 37.5%  62.5%  
PB3 
 
Patient well-being              0.0%         
25.0% 




Negative recommendation 0.0%         
12.5% 
  75.0% 12.5%    0.0%  
Cognitive      
Cog1 Analytical mind                  0.0%           
0.0% 
 12.5% 87.5%  0.0%  
Cog2 
 
Intellectual challenge          0.0%           
0.0% 
 12.5% 87.5%  0.0%  
Cog3 
 
Improve skills                     0.0%           
0.0% 
 25.0% 75.0%  0.0%  
Cog4 Logical thinking                  0.0%          
0.0% 
 





             The providers' pre-motivation scale (Table 7) revealed a 62.5 to 50% agreement to 
support pharmacogenomics' adoption concerning practicality, time-saving and technological 
reliability. The group was 50% neutral to conform expectations and utilization of PGx; at the 
same time, there were 37.5 to 25% in disagreement to attune to expectations and been pressured 
by the majority to use the technology. Similarly, they disagreed a 50 to 37.5% about the power to 
achieve recognition, become a key leader, and increase their earnings with pharmacogenomics' 
adoption. The participants were 50.0% neutral in advancing careers, impacting decision-making, 
and the benefit of being a pioneer in PGx. 
          The area of hedonics or to enjoy the adoption of pharmacogenomics technology had 
excellent scores with 87.5% in agreement. Seventy-five percent of the group agreed with the 
satisfaction and excitement of acquiring medical innovations, and 50.0% were enthusiastic about 
testing a medical innovation. 
 About patient benefits from pharmacogenomics, 62.5% strongly agreed to adopt the 
technology if it increases the patients' comfort. However, 75.0% were neutral about adopting the 
technology if there were harmful recommendations. The cognitive construct or understanding 
and knowledge to adopt pharmacogenomics had the highest scores with 87.5% in analysis, 
intellectual challenge, and logical thinking; they scored a 75.0% in the combined medical and 
intellectual skills. The responses in this area support the fact that clinical providers are highly 
motivated to pursue knowledge to improve patient care. A higher group response will be more 
significant to identify their preferences better.  
Participants Comments 
Comments received in the open text space included:  




“The interpretation of the testing is often cursory and confusing. Physicians have been trained to 
read diagnostic testing not as interpreters but as utilizers of bottom line data. Many insurances 
will not cover genomics unless failed STAR D trials from multiple categories is demonstrated.” 
“The conformity and power questions seem applicable for prescribers not for clinicians. A more 
broad and direct question like, “I support genetic testing for the best client care” would be 
better, in my opinion.” – a clinician 
Post-Participants Motivation to Adopt 
          Video education in pharmacogenomics was provided via email to the 27 healthcare 
participants. Of this group, only three people responded to the Post-PMA scale after multiple 
reminders. The DNP student received verbal feedback that the presentation was good but too 
complex, so perhaps that is why not many surveys were returned. The video education was 
technical in terms of the clinical use of pharmacogenomics and understanding the reports. 
Perhaps a series of in-person sessions after the project is complete can be developed for an 
extended discussion of the technology and case by case application.  
 
Discussion 
          This quality improvement project's main goal was to identify the value of 
pharmacogenomic testing (PGx) in adult patients diagnosed with major depression (MDD) who 
have failed two or more antidepressants and had PGx for treatment guidance. Records review of 
pre-post PHQ-9 depression scale scores in 73 subjects demonstrated response to treatment with a 
decrease of 10 points in the scores mean. The secondary goal assessing providers' motivation to 
adopt pharmacogenomic testing before and after an educational intervention in the topic revealed 




          The results from a convenience sample of 73 records of patients showed a predominant 
group of 72.6% females vs. 27.4% males, White European-American (86.3%) with an average 
age of 44.85 years old. There was a small representation of Hispanics (8.2%) and African-
American (5.5%) subjects. These groups are a segment of the Hampshire, MA area where the 
U.S. census identified an 84% White (European-American), 4.01% White Hispanic, and  2.69% 
Black or African American (DATA USA, 2018). Brody et al. (2018) found in the U.S. National 
Health and Nutrition Examination Survey twice the rate of depression in women 10.4% than 
males with a 5.5%. The previous data and the number of females in the sample reflect that more 
females are diagnosed with major depression and seek treatment.  
          The STAR-D study data (NIMH, 2006) demonstrated that 45.2% of the subjects failed an 
average of four or more medications before treatment response. In synchrony with the STAR-D 
study, this record review found a 23% of subjects failed four medications, 21.9% failed eight to 
eleven and, 20.5% failed five to seven medications before pharmacogenomic testing (PGx). We 
can estimate that the total sum of these subgroups, 65.4% of the subjects, failed an average of six 
antidepressants before PGx. After the guided pharmacogenomic intervention, 44 (60.3%) of the 
subjects responded to an average of 1.36 medications. It is worth mentioning a subgroup of 18 
(24.7%) subjects had two to four medication trials post PGx.  
          There was a difference of 10 points from the PHQ-9 scales pre-post mean values (Table 2 
& 3) with p = .000 < .001 indicating subjects had a positive and significant response to 
pharmacogenomic guided medication. Twenty-two 22 (33%) subjects had scores within 
remission “0 – 4 none to minimal depression”, and 35 (53%) had “5 – 9 mild depression”. These 




responded to treatment, and 21.5% had remission. Similarly, Perez et al. (2017) found a higher 
response in PGx guided group than treatment as usual, 51.3% vs. 36.1%; alike, Tanner et al. 
(2018) found 31% response and 15.2% remission rates in subjects with pharmacogenomic 
testing.  
          The inclusion of the comorbid diagnoses, borderline personality disorder and history of 
substance use had the additional purpose of identifying these subgroups' in the treatment-
resistant depression population and exploring their response to pharmacogenomic testing. 
Chapman et al. (2020) identified the epidemiology of the diagnosis of borderline personality 
disorder (BPD) with a prevalence of 1.6%  in the general population, a lifetime prevalence of 
5.9%, and a 3:1 ratio of females vs. males in the mental health scenarios. The subjects sample 
had a similar proportion of 15 females to four males diagnosed with BPD, almost 3:1 ratio.   
          Even though the overlap of 12 subjects in the substance use history and the BPD 
subgroups, the results were significantly higher 10% > 1.5% in the history of substance use 
subjects for remission "0 – 4 none to minimal depression", and 18% > 12% for response "5 – 9 
mild depression" than the BPD subgroup. These findings serve to make a distinction between 
genotypic and phenotypic correlates of the phenomenology of depression. Some symptoms 
evolved from learned behaviors, and some symptoms stem from presumed catecholamine 
neurobiology. Indeed, the results support the challenges of treating comorbid borderline 
personality disorder (Chapman et al., 2020), requiring a multidisciplinary approach. It also 
suggests the use of pharmacogenomic testing may improve response to psychotropic treatment in 
the BPD subgroup. 
          The 73 subjects' phenotype findings returned a predominant White European-American 




the intermediate metabolizer (IM) enzymes with  CYP2B6 37%, CYP2C9 35.6%, CYP2C19 
20.5%, UGT2B15 21.9%, and  CYP2D6 19.2% (note CYP2D6 had the highest value 11% as 
poor metabolizer). A worldwide meta-analysis from Zhou et al. (2017) found a 4.3% reduced 
CYP2B6 in Europeans vs. 4.4% admixed Americans, reduced CYP2C9 18% European vs. 
10.8% admixed Americans, reduced CYP2C19 18.5% Europeans vs. 10.7% admixed Americans, 
and reduced CYP2D6 29.5% European vs. 25.3%  admixed Americans.  
          The revision results correlate with the literature review that those individuals in the poor 
metabolizers, intermediate or ultra-rapid groups, who already failed two antidepressants, will 
require medication dose adjustment or an alternative antidepressant due to their metabolic 
deficits (Bank et al., 2018; Dunlop et al., 2019; Greden et al., 2019; Hicks et al., 2015; Pérez et 
al., 2017). Furthermore, the treatment implications for the identified genotypes based on Fabbri 
and Serretti (2019) and their summary of the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) and the Dutch Pharmacogenetics Working Group in the Netherlands for the 
dosing of antidepressants recommend a dose decrease of 25% to 50% in individuals who are 
intermediate or poor metabolizers or avoid drugs processed by those enzymes. 
           Despite the participants' limited responses, their main areas of agreement with 87.5% to 
75% were the joy to learn and test new technology and the intellectual gain and medical 
knowledge derived from the new information. The second most substantial areas with a 62.5% to 
50% agreement were the practical time saving and reliability of pharmacogenomics and patient 
comfort. The group's most significant disagreement scores were 50% to 37.5% in conformity to 
expectations to use pharmacogenomics based on peer or social pressure, the power of receiving 





Facilitators and Barriers 
          The agency administrative director and medical director were the main facilitators to 
support this project with the records review and staff surveys. A limitation for the record review 
was excluding other patients' diagnoses (e.g., bipolar disorder, anxiety disorder). A systematic 
review and meta-analysis from Milosavljević et al. (2021) supported genotyping for CYP2D6 
and CYP2C19 for dose recommendations after associating elevated drug levels in several 
antipsychotics and antidepressants to individuals genotype deficits. The treatment of depression 
and other mood disorders often requires the concomitant use of antidepressants, antipsychotics, 
and other adjunct psychotropics; therefore, PGx will identify genotype deficits in the CYP 450 
enzymes and other relevant genes to prevent adverse events or lack of treatment response.  
          There were 30 missing values from the pre-post PHQ-9 scales, a barrier to complete the 
data. This required contacting patients by phone to update their information and calculate their 
pre PHQ-9 scores before PGx from their documented symptoms in the electronic health record 
and patients' confirmation. The agency facilitated a team of nurses to assist with the calls to 
complete a meaningful sample of the scales. The timing of these calls during the current COVID 
quarantine and its impact on our society's social and financial changes may have contributed to 
higher depression scores in the post-PHQ-9 scales. 
          The possibility of recent PHQ-9 scores not representing the response to treatment but to 
the traumatic pandemic experience is both a barrier and an opportunity to use a measurement 
instrument. The consistent use of validated clinical instruments or measurement-based care 
(MBC) is believed to be less than 20% in mental health care, despite proven to substantiate 




therapies reimbursement (Aboraya et al., 2018; Lewis et al., 2019). Incorporating  efficient, 
valid, and reliable instruments for MBC is an agency clinical-policy decision that will result in 
the previously mentioned benefits.  
          There was a limitation to obtain inferential data between the subgroups of borderline 
personality disorder and substance use history due to their overlap. A more significant sample 
may exclude the overlap values to comply with inferential analysis's assumption of 
independence. 
          Several barriers may contribute to the providers' surveys' low response; the current 
COVID quarantine keeps most staff working from home, with increased demand for virtual 
work. The new virtual work reality may be an additional task and an obstacle for providers to 
respond to a survey and watch the video education. Other factors include the providers' 
perception of the complexity of understanding the pharmacogenomic technology vs. its debated 
reliability. Chronic time restrictions in the health system with a constraint of 15 minutes for  
medication follow up visits is a significant barrier to promote the appropriate use of PGx. 
Finally, since medical providers are the primary users of the technology, the non-medical 
providers may feel the technology and survey were not relevant to their needs or interest.        
          The previously discussed barriers to the project align with the theoretical framework of the 
Diffusion of Innovation Theory by Everett Rogers (2003). Individuals need time to adopt new 
ideas which will be influenced by their views and knowledge of the innovation attributes. Rogers 
states that the rate of adoption is not dependent on the awareness-knowledge of the innovation. 
The participants' perception of its advantage, compatibility with their work, complexity, and 




adopt pre-scale evidenced the participants' motivation and joy to adopt new knowledge, agreed 
with new technology's practicality, and patients' benefit. The low response to the post-PMA did 
not allow the student to identify motivation adoption changes post the video education.    
          Pharmacogenomic testing has been available for patients in Medicare, Medicaid, and some 
commercial insurances for more than ten years. Last June 2020, Medicare updated their medical 
necessity "Local Coverage Determination" (LCD) of pharmacogenomics testing for medications 
with known gene-drug interaction established by FDA or the CPIC guidelines (American Society 
of Health-System Pharmacists [ASHP], 2020). From a participant's comment, it is a limitation to 
use PGx when most insurances, particularly commercial, require the failure of more than two 
medications as recommended in the STAR-D multiple categories.  
          Healthcare cost analysis offers a realistic view of the high cost of psychiatric care related 
to psychotropic medication failures, including patients continuing to be depressed, unable to 
function in society, and the additional cost of healthcare utilization due to side effects, adverse 
events, or hospitalizations. The cost benefits of using pharmacogenomic testing include a 
potential health care savings for one individual of over $3,000.00 dollars a year with the use of 
genetically congruent medications (Sussman Et Al., 2019).           
          Finally, Rogers (2003) points that organizational decisions have a slower rate than an 
individual's choice. The inclusion of administrative staff in this project seeks to expand the 
information cascade to promote pharmacogenomic’s adoption. The final attribute of an 
innovation is its observability. The patients, providers, and administrators must observe the 
benefits of a health intervention, confirming the necessary evidence for its adoption. Therefore, 




the PGx guided intervention is instrumental in demonstrating the value of pharmacogenomic 
testing in patients' care. 
Conclusion 
          This DNP project evaluated the use of pharmacogenomic testing as a treatment resource 
for adult patients diagnosed with major depression that failed two or more antidepressants, 
measured by changes in the PHQ-9 depression scale pre and post pharmacogenomic guided 
medication.  The results demonstrated a significant decrease of 10 points mean in the post PHQ-
9 scores with p = .000 < .001 for treatment response (5 – 9 mild depression) in 53% of the 
subjects, and 33% had scores within remission (0 – 4 none to minimal depression). A 60.3% of 
patients responded to an average of 1.3 medications, and 24.7% had 2 to 4 medications post 
pharmacogenomic treatment. These are significant findings under the new evidence research in 
pharmacogenomics. The results are from the community population, which is burdened by social 
disadvantages, substance use, and chronic mental illness.   
          This project provides many opportunities to continue exploring the associated factors 
contributing to subjects' response to PGx: their gender, age, education, comorbid diagnosis, 
medications, and genotypes. Bigger sample size will provide a better representation for statistical 
inferences. A post-hoc analysis of some of the above variables may uncover information that was 
not part of the primary goal. 
          Time is a natural barrier in any innovation; the last ten years in pharmacogenomics 
research offered new evidence-based data that contribute to its diffusion of information. 
Providers pre-survey demonstrated their motivation and joy for new knowledge and technology 




increased motivation to adopt pharmacogenomics. A continuous dialogue in pharmacogenomics 
and case discussions will be more appropriate to apply the information for clinical needs, and a 
more straightforward presentation for staff might be better received. The CPIC and Dutch 
Consortium guidelines for antidepressants and SSRIs are an excellent guide for prescribers to 
review medications metabolized by the hepatic P450 isoenzymes and their clinical practice 
implications. The guidelines apply to medication management in all medical specialties.  
Nurses need to participate in pharmacogenomics clinical projects, continuing education 
in the technology, and assuming an active role in promoting evidence-based diagnostics and 
therapies that will improve patient care and safety. The agency adopted this project to continue 
using, evaluating, and documenting pharmacogenomic testing benefits in patients' care. The 
student plans to continue reporting referred patients’ responses to PGx, sharing the information 
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Goals, Objectives and Expected Outcomes 
 
Goal 1: Value of pharmacogenomic testing in adults diagnosed MDD who have failed two or 
more medications 
            
                  Objectives                                                                                 Outcomes 
    
   Evaluate response to pharmacogenomic 
   guided medications in patients   
   examined from 2018 to 2020 with the  




Patients will show decreased 
symptoms, improved treatment 
response, and remission evidenced by 
the Patient Health Questionnaire - 9 
scale with five or less points by 
February 2021.        
 
Goal 2: Promote pharmacogenomic testing adoption and use in medical providers 
     
Objectives                                                                           Outcomes 
   
   Assess providers’ motivation to adopt  
   pharmacogenomic testing with the  
   administration of the provider  
   motivation adoption scale (PMA scale) 
   by October 2020. 
 
   Promote providers’ adoption of  
   pharmacogenomic testing with  
   education in the topic by November  
   2020; and re-evaluate motivation with 
   PMA scale by February 2021.  
 
 
Establish providers’ motivation 
baseline toward the use of 
pharmacogenomic testing with PMA 
scale by November 2020. 
 
 
Increase providers’ motivation to 
adopt and use pharmacogenomic 
testing with education in the area, 
measured by positive changes in scores 










Source: Gaynes, B. N., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Spencer, D., & Fava, M. (2008).  
          The STAR*D study: Treating depression in the real world. Cleveland Clinic Journal of  






Harvard South Shore Program: Unipolar Depression Algorithm 
 
 
Source: Giakoumatos, C. I. & Osser, D. (2017). The psyhcopharmacology algorithm project at the 
         Harvard South Shore Program: An update on unipolar nonpsychotic depression. Harvard Review of 
















DNP Project Timeline   
                                           
  Fall 2020 – Spring 2021 
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